OTCMKTS:STDAF - Stada Arzneimittel Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$94.05 0.00 (0.00 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$94.05
Today's Range$94.05 - $94.05
52-Week Range$64.91 - $108.40
VolumeN/A
Average Volume10 shs
Market Capitalization$5.86 billion
P/E Ratio27.83
Dividend YieldN/A
Beta0.83
Stada Arzneimittel logoSTADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.

Receive STDAF News and Ratings via Email

Sign-up to receive the latest news and ratings for STDAF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:STDAF
CUSIPN/A
Phone49-6101-6030

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio27.83
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.61 billion
Price / Sales2.24
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares62,340,000

Stada Arzneimittel (OTCMKTS:STDAF) Frequently Asked Questions

What is Stada Arzneimittel's stock symbol?

Stada Arzneimittel trades on the OTCMKTS under the ticker symbol "STDAF."

How were Stada Arzneimittel's earnings last quarter?

Stada Arzneimittel (OTCMKTS:STDAF) posted its quarterly earnings data on Thursday, May, 3rd. The company reported $1.20 EPS for the quarter. The firm earned $685.72 million during the quarter. View Stada Arzneimittel's Earnings History.

When is Stada Arzneimittel's next earnings date?

Stada Arzneimittel is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Stada Arzneimittel.

Who are some of Stada Arzneimittel's key competitors?

Who are Stada Arzneimittel's key executives?

Stada Arzneimittel's management team includes the folowing people:
  • Dr. Claudio Albrecht, Chairman of the Exec. Board & CEO (Age 59)
  • Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 61)
  • Dr. Barthold Piening, Chief Technical Operations Officer & Member of Exec. Board (Age 60)
  • Ms. Leslie Isabelle Iltgen, VP of Investor Relations
  • Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 43)

Has Stada Arzneimittel been receiving favorable news coverage?

Headlines about STDAF stock have trended positive recently, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Stada Arzneimittel earned a coverage optimism score of 0.26 on Accern's scale. They also assigned media coverage about the company an impact score of 45.72 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Stada Arzneimittel?

Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stada Arzneimittel's stock price today?

One share of STDAF stock can currently be purchased for approximately $94.05.

How big of a company is Stada Arzneimittel?

Stada Arzneimittel has a market capitalization of $5.86 billion and generates $2.61 billion in revenue each year.

How can I contact Stada Arzneimittel?

Stada Arzneimittel's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at 49-6101-6030.


MarketBeat Community Rating for Stada Arzneimittel (STDAF)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Stada Arzneimittel and other stocks. Vote "Outperform" if you believe STDAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.